#skbioscience — Public Fediverse posts

SK Bioscience strengthens production cooperation with subsidiary IDT Biologika for second-generation Zaire Ebola vaccine development with MSD, expanding its global vaccine production network to address infectious disease outbreaks in Africa including Democratic Republic of Congo.
#YonhapInfomax #SKBioscience #EbolaVaccine #MSD #IDTBiologika #ContractManufacturing #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=111388

SK Bioscience strengthens production cooperation with subsidiary IDT Biologika for second-generation Zaire Ebola vaccine development with MSD, expanding its global vaccine production network to address infectious disease outbreaks in Africa including Democratic Republic of Congo.
#YonhapInfomax #SKBioscience #EbolaVaccine #MSD #IDTBiologika #ContractManufacturing #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=111388

SK Bioscience strengthens production cooperation with subsidiary IDT Biologika for second-generation Zaire Ebola vaccine development with MSD, expanding its global vaccine production network to address infectious disease outbreaks in Africa including Democratic Republic of Congo.
#YonhapInfomax #SKBioscience #EbolaVaccine #MSD #IDTBiologika #ContractManufacturing #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=111388

SK Bioscience strengthens production cooperation with subsidiary IDT Biologika for second-generation Zaire Ebola vaccine development with MSD, expanding its global vaccine production network to address infectious disease outbreaks in Africa including Democratic Republic of Congo.
#YonhapInfomax #SKBioscience #EbolaVaccine #MSD #IDTBiologika #ContractManufacturing #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=111388

SK Bioscience Co. narrowed its Q4 operating loss to KRW 51.6 billion as revenue surged 17.4% year-on-year, driven by subsidiary IDT’s turnaround and robust vaccine sales.
#YonhapInfomax #SKBioscience #OperatingLoss #Q4Earnings #IDTBiologika #VaccineSales #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=103615

SK Bioscience Co. narrowed its Q4 operating loss to KRW 51.6 billion as revenue surged 17.4% year-on-year, driven by subsidiary IDT’s turnaround and robust vaccine sales.
#YonhapInfomax #SKBioscience #OperatingLoss #Q4Earnings #IDTBiologika #VaccineSales #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=103615

SK Bioscience Co. narrowed its Q4 operating loss to KRW 51.6 billion as revenue surged 17.4% year-on-year, driven by subsidiary IDT’s turnaround and robust vaccine sales.
#YonhapInfomax #SKBioscience #OperatingLoss #Q4Earnings #IDTBiologika #VaccineSales #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=103615

SK Bioscience Co. narrowed its Q4 operating loss to KRW 51.6 billion as revenue surged 17.4% year-on-year, driven by subsidiary IDT’s turnaround and robust vaccine sales.
#YonhapInfomax #SKBioscience #OperatingLoss #Q4Earnings #IDTBiologika #VaccineSales #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=103615

SK Chemicals Co. returned to profit in Q3 2025, posting a 43.1% revenue jump and positive operating profit, fueled by improved results at subsidiary SK Bioscience and robust sales in core business divisions.
#YonhapInfomax #SKChemicals #SKBioscience #OperatingProfit #Q3Earnings #RevenueGrowth #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=89396

SK Chemicals Co. returned to profit in Q3 2025, posting a 43.1% revenue jump and positive operating profit, fueled by improved results at subsidiary SK Bioscience and robust sales in core business divisions.
#YonhapInfomax #SKChemicals #SKBioscience #OperatingProfit #Q3Earnings #RevenueGrowth #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=89396

SK Chemicals Co. returned to profit in Q3 2025, posting a 43.1% revenue jump and positive operating profit, fueled by improved results at subsidiary SK Bioscience and robust sales in core business divisions.
#YonhapInfomax #SKChemicals #SKBioscience #OperatingProfit #Q3Earnings #RevenueGrowth #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=89396

SK Chemicals Co. returned to profit in Q3 2025, posting a 43.1% revenue jump and positive operating profit, fueled by improved results at subsidiary SK Bioscience and robust sales in core business divisions.
#YonhapInfomax #SKChemicals #SKBioscience #OperatingProfit #Q3Earnings #RevenueGrowth #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=89396

IDT Biologika, the European subsidiary of SK Bioscience, is ramping up efforts to secure global CDMO contracts by participating in major industry events and leveraging synergies with its parent company.
#YonhapInfomax #SKBioscience #IDTBiologika #CDMO #VaccineMarket #GlobalOrders #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=89250

IDT Biologika, the European subsidiary of SK Bioscience, is ramping up efforts to secure global CDMO contracts by participating in major industry events and leveraging synergies with its parent company.
#YonhapInfomax #SKBioscience #IDTBiologika #CDMO #VaccineMarket #GlobalOrders #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=89250

IDT Biologika, the European subsidiary of SK Bioscience, is ramping up efforts to secure global CDMO contracts by participating in major industry events and leveraging synergies with its parent company.
#YonhapInfomax #SKBioscience #IDTBiologika #CDMO #VaccineMarket #GlobalOrders #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=89250

IDT Biologika, the European subsidiary of SK Bioscience, is ramping up efforts to secure global CDMO contracts by participating in major industry events and leveraging synergies with its parent company.
#YonhapInfomax #SKBioscience #IDTBiologika #CDMO #VaccineMarket #GlobalOrders #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=89250

SK Bioscience narrowed its Q3 operating loss to KRW 19.4 billion as revenue soared 145% year-on-year, driven by vaccine growth and the IDT Biologika acquisition.
#YonhapInfomax #SKBioscience #OperatingLoss #RevenueGrowth #IDTBiologika #VaccineMarket #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=88934

SK Bioscience narrowed its Q3 operating loss to KRW 19.4 billion as revenue soared 145% year-on-year, driven by vaccine growth and the IDT Biologika acquisition.
#YonhapInfomax #SKBioscience #OperatingLoss #RevenueGrowth #IDTBiologika #VaccineMarket #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=88934

SK Bioscience narrowed its Q3 operating loss to KRW 19.4 billion as revenue soared 145% year-on-year, driven by vaccine growth and the IDT Biologika acquisition.
#YonhapInfomax #SKBioscience #OperatingLoss #RevenueGrowth #IDTBiologika #VaccineMarket #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=88934

SK Bioscience narrowed its Q3 operating loss to KRW 19.4 billion as revenue soared 145% year-on-year, driven by vaccine growth and the IDT Biologika acquisition.
#YonhapInfomax #SKBioscience #OperatingLoss #RevenueGrowth #IDTBiologika #VaccineMarket #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=88934

SK Chemicals will issue 220 billion won ($160 million) in exchangeable bonds backed by SK Bioscience shares to repay debt and reduce interest costs, aiming to strengthen its financial structure.
#YonhapInfomax #SKChemicals #ExchangeableBonds #SKBioscience #DebtRepayment #InterestCosts #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=82605

SK Chemicals will issue 220 billion won ($160 million) in exchangeable bonds backed by SK Bioscience shares to repay debt and reduce interest costs, aiming to strengthen its financial structure.
#YonhapInfomax #SKChemicals #ExchangeableBonds #SKBioscience #DebtRepayment #InterestCosts #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=82605

SK Chemicals will issue 220 billion won ($160 million) in exchangeable bonds backed by SK Bioscience shares to repay debt and reduce interest costs, aiming to strengthen its financial structure.
#YonhapInfomax #SKChemicals #ExchangeableBonds #SKBioscience #DebtRepayment #InterestCosts #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=82605

SK Chemicals will issue 220 billion won ($160 million) in exchangeable bonds backed by SK Bioscience shares to repay debt and reduce interest costs, aiming to strengthen its financial structure.
#YonhapInfomax #SKChemicals #ExchangeableBonds #SKBioscience #DebtRepayment #InterestCosts #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=82605

Bill Gates, during a meeting with President Lee Jae-myung in Seoul, praised South Korea's rapid advances in bioscience and highlighted the nation's key role in global vaccine and health innovation.
#YonhapInfomax #BillGates #LeeJaeMyung #Bioscience #VaccineDevelopment #SKBioscience #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=78001

Bill Gates, during a meeting with President Lee Jae-myung in Seoul, praised South Korea's rapid advances in bioscience and highlighted the nation's key role in global vaccine and health innovation.
#YonhapInfomax #BillGates #LeeJaeMyung #Bioscience #VaccineDevelopment #SKBioscience #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=78001

Bill Gates, during a meeting with President Lee Jae-myung in Seoul, praised South Korea's rapid advances in bioscience and highlighted the nation's key role in global vaccine and health innovation.
#YonhapInfomax #BillGates #LeeJaeMyung #Bioscience #VaccineDevelopment #SKBioscience #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=78001

Bill Gates, during a meeting with President Lee Jae-myung in Seoul, praised South Korea's rapid advances in bioscience and highlighted the nation's key role in global vaccine and health innovation.
#YonhapInfomax #BillGates #LeeJaeMyung #Bioscience #VaccineDevelopment #SKBioscience #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=78001

SK Bioscience and the Gates Foundation reaffirmed and expanded their partnership on global health, focusing on next-generation vaccines and pandemic preparedness during Bill Gates’ visit to South Korea.
#YonhapInfomax #SKBioscience #GatesFoundation #VaccineDevelopment #GlobalHealth #PandemicPreparedness #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=77952

SK Bioscience and the Gates Foundation reaffirmed and expanded their partnership on global health, focusing on next-generation vaccines and pandemic preparedness during Bill Gates’ visit to South Korea.
#YonhapInfomax #SKBioscience #GatesFoundation #VaccineDevelopment #GlobalHealth #PandemicPreparedness #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=77952

SK Bioscience and the Gates Foundation reaffirmed and expanded their partnership on global health, focusing on next-generation vaccines and pandemic preparedness during Bill Gates’ visit to South Korea.
#YonhapInfomax #SKBioscience #GatesFoundation #VaccineDevelopment #GlobalHealth #PandemicPreparedness #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=77952

SK Bioscience and the Gates Foundation reaffirmed and expanded their partnership on global health, focusing on next-generation vaccines and pandemic preparedness during Bill Gates’ visit to South Korea.
#YonhapInfomax #SKBioscience #GatesFoundation #VaccineDevelopment #GlobalHealth #PandemicPreparedness #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=77952

SK Bioscience and Sanofi have completed an expanded pneumococcal vaccine production facility in Andong, strengthening their global partnership and advancing the launch of a next-generation 21-valent vaccine.
#YonhapInfomax #SKBioscience #Sanofi #PneumococcalVaccine #PCV21 #VaccineProductionFacility #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=69860

SK Bioscience Co. has completed the expansion of its Andong L House vaccine facility, securing new production capacity for its next-generation pneumococcal vaccine developed with Sanofi, and aims for global cGMP certification.
#YonhapInfomax #SKBioscience #Sanofi #VaccineProduction #GBP410 #AndongLHouse #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=65242

SK Bioscience Co. has completed the expansion of its Andong L House vaccine facility, securing new production capacity for its next-generation pneumococcal vaccine developed with Sanofi, and aims for global cGMP certification.
#YonhapInfomax #SKBioscience #Sanofi #VaccineProduction #GBP410 #AndongLHouse #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=65242

SK Bioscience Co. has completed the expansion of its Andong L House vaccine facility, securing new production capacity for its next-generation pneumococcal vaccine developed with Sanofi, and aims for global cGMP certification.
#YonhapInfomax #SKBioscience #Sanofi #VaccineProduction #GBP410 #AndongLHouse #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=65242

SK Bioscience Co. has completed the expansion of its Andong L House vaccine facility, securing new production capacity for its next-generation pneumococcal vaccine developed with Sanofi, and aims for global cGMP certification.
#YonhapInfomax #SKBioscience #Sanofi #VaccineProduction #GBP410 #AndongLHouse #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=65242

SK Bioscience Co. has completed the expansion of its Andong L House vaccine facility, securing new production capacity for its next-generation pneumococcal vaccine developed with Sanofi, and aims for global cGMP certification.
#YonhapInfomax #SKBioscience #Sanofi #VaccineProduction #GBP410 #AndongLHouse #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=65242

SK Bioscience wins patent lawsuit against Pfizer, paving way for pneumococcal vaccine sales and potentially reshaping global vaccine market dynamics
#YonhapInfomax #SKBioscience #PatentLawsuit #Pfizer #PneumococcalVaccine #SupremeCourt #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64108

SK Bioscience wins patent lawsuit against Pfizer, paving way for pneumococcal vaccine sales and potentially reshaping global vaccine market dynamics
#YonhapInfomax #SKBioscience #PatentLawsuit #Pfizer #PneumococcalVaccine #SupremeCourt #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64108

SK Bioscience wins patent lawsuit against Pfizer, paving way for pneumococcal vaccine sales and potentially reshaping global vaccine market dynamics
#YonhapInfomax #SKBioscience #PatentLawsuit #Pfizer #PneumococcalVaccine #SupremeCourt #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64108

SK Bioscience wins patent lawsuit against Pfizer, paving way for pneumococcal vaccine sales and potentially reshaping global vaccine market dynamics
#YonhapInfomax #SKBioscience #PatentLawsuit #Pfizer #PneumococcalVaccine #SupremeCourt #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64108

SK Bioscience wins patent lawsuit against Pfizer, paving way for pneumococcal vaccine sales and potentially reshaping global vaccine market dynamics
#YonhapInfomax #SKBioscience #PatentLawsuit #Pfizer #PneumococcalVaccine #SupremeCourt #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64108

SK Bioscience reports Q1 operating loss of 15.1 billion won, outperforming market expectations, with sales surge of 594% year-on-year driven by IDT Biologika acquisition and strong vaccine sales
#YonhapInfomax #SKBioscience #Q1Earnings #OperatingLoss #VaccineSales #IDTBiologika #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=61992

SK Bioscience reports Q1 operating loss of 15.1 billion won, outperforming market expectations, with sales surge of 594% year-on-year driven by IDT Biologika acquisition and strong vaccine sales
#YonhapInfomax #SKBioscience #Q1Earnings #OperatingLoss #VaccineSales #IDTBiologika #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=61992

SK Bioscience reports Q1 operating loss of 15.1 billion won, outperforming market expectations, with sales surge of 594% year-on-year driven by IDT Biologika acquisition and strong vaccine sales
#YonhapInfomax #SKBioscience #Q1Earnings #OperatingLoss #VaccineSales #IDTBiologika #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=61992

SK Bioscience reports Q1 operating loss of 15.1 billion won, outperforming market expectations, with sales surge of 594% year-on-year driven by IDT Biologika acquisition and strong vaccine sales
#YonhapInfomax #SKBioscience #Q1Earnings #OperatingLoss #VaccineSales #IDTBiologika #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=61992

SK Bioscience reports Q1 operating loss of 15.1 billion won, outperforming market expectations, with sales surge of 594% year-on-year driven by IDT Biologika acquisition and strong vaccine sales
#YonhapInfomax #SKBioscience #Q1Earnings #OperatingLoss #VaccineSales #IDTBiologika #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=61992

SK Bioscience reports Q1 operating loss of 15.1 billion won, outperforming market expectations with 594% year-on-year sales growth despite continued losses
#YonhapInfomax #SKBioscience #Q1Earnings #OperatingLoss #SalesGrowth #MarketExpectations #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=61988

SK Bioscience reports Q1 operating loss of 15.1 billion won, outperforming market expectations amid challenging biotech landscape
#YonhapInfomax #SKBioscience #Q1Results #OperatingLoss #BiotechIndustry #FinancialPerformance #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=61986